Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients
Launched by BASKENT UNIVERSITY · Feb 9, 2006
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
The first study to evaluate the effects of troglitazone on blood pressure in humans was published recently, which demonstrated a 5/4 mm Hg reduction in ambulatory blood pressure in 18 nondiabetic obese subjects after 12 weeks' treatment. Another study in 18 hypertensive subjects with diabetes mellitus showed an 18/12 mm Hg decline in office blood pressure after 8 weeks of treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Blood pressure of patients were in normotensive limits according to the JNC VII
- • Diabetes mellitus treated with oral antidiabetics or diet
- Exclusion Criteria:
- • Any known hypertension, coronary artery disease, congestive hearth failure, renal disease or liver disease
- • Anti-hypertensive treatment
About Baskent University
Baskent University is a distinguished academic and research institution dedicated to advancing healthcare through innovative clinical trials and studies. With a strong emphasis on evidence-based medicine, the university collaborates with a network of healthcare professionals and researchers to design and implement rigorous clinical research that aims to improve patient outcomes. Baskent University is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring the integrity and reliability of its research initiatives while fostering a collaborative environment that promotes scientific discovery and education.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, , Turkey
Patients applied
Trial Officials
Neslihan B Tutuncu, MD
Study Director
Medical Doctor, Endocrynology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials